Page 53 - IMO-2-1

Innovative Medicines & Omics Current approach in the management of kidney disease

26. Tanaka S, Okusa MD. Crosstalk between the nervous system chronic kidney disease stages 3-5: A network meta-analysis
and the kidney. Kidney Int. 2020;97(3):466-476. of randomised clinical trials. Drugs. 2020;80(8):797-811.
doi: 10.1016/j.kint.2019.10.032 doi: 10.1007/s40265-020-01290-3
27. Sata Y, Head GA, Denton K, May CN, Schlaich MP. Role of 36. Brar S, Ye F, James MT, et al. Association of angiotensin-
the sympathetic nervous system and its modulation in renal converting enzyme inhibitor or angiotensin receptor blocker
hypertension. Front Med (Lausanne). 2018;5:82. use with outcomes after acute kidney injury. JAMA Intern
Med. 2018;178(12):1681-1690.
doi: 10.3389/fmed.2018.00082
doi: 10.1001/jamainternmed.2018.4749
28. An J, Niu F, Sim JJ. Cardiovascular and kidney outcomes
of spironolactone or eplerenone in combination with 37. Wu LS, Chang SH, Chang GJ, et al. A comparison between
ACEI/ARBs in patients with diabetic kidney disease. angiotensin converting enzyme inhibitors and angiotensin
Pharmacotherapy. 2021;41(12):998-1008. receptor blockers on end stage renal disease and major
doi: 10.1002/phar.2633 adverse cardiovascular events in diabetic patients:
A population-based dynamic cohort study in Taiwan.
29. Li EC, Heran BS, Wright JM. Angiotensin converting Cardiovasc Diabetol. 2016;15:56.
enzyme (ACE) inhibitors versus angiotensin receptor
blockers for primary hypertension. Cochrane Database Syst doi: 10.1186/s12933-016-0365-x
Rev. 2014;2014(8):CD009096. 38. Bhandari S, Mehta S, Khwaja A, et al. Renin-angiotensin
system inhibition in advanced chronic kidney disease.
doi: 10.1002/14651858.CD009096.pub2
N Engl J Med. 2022;387(22):2021-2032.
30. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/
AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/ doi: 10.1056/NEJMoa2210639
PCNA Guideline for the prevention, detection, evaluation, 39. Tang SCW, Chan KW, Ip DKM, et al. Direct renin
and management of high blood pressure in adults: A inhibition in non-diabetic chronic kidney disease (DRINK):
Report of the American College of Cardiology/ American A prospective randomized trial. Nephrol Dial Transplant.
Heart association task force on clinical practice guidelines. 2021;36(9):1648-1656.
Hypertension. 2018;71(6):e140-e144.
doi: 10.1093/ndt/gfaa085
doi: 10.1161/HYP.0000000000000065
40. Cernaro V, Loddo S, Macaione V, et al. RAS inhibition
31. Chen JY, Tsai IJ, Pan HC, et al. The impact of angiotensin- modulates kynurenine levels in a CKD population with
converting enzyme inhibitors or angiotensin II receptor and without type 2 diabetes mellitus. Int Urol Nephrol.
blockers on clinical outcomes of acute kidney disease 2020;52(6):1125-1133.
patients: A systematic review and meta-analysis. Front
Pharmacol. 2021;12:665250. doi: 10.1007/s11255-020-02469-z
41. Sica DA. Renin-Angiotensin blockade: Therapeutic agents.
doi: 10.3389/fphar.2021.665250
In; Textbook of Nephro-Endocrinology. United States
32. Tada K, Nakano Y, Takahashi K, et al. Current use of Academic Press; 2018. p. 57-75.
angiotensin II receptor blockers and angiotensin-converting
enzyme inhibitors for hypertension in patients with chronic 42. Tang SCW, Yiu WH. Innate immunity in diabetic kidney
disease. Nat Rev Nephrol. 2020;16(4):206-222.
kidney disease with proteinuria: A cross-sectional study
based on real-world data. Hypertens Res. 2024;28:244-255.. doi: 10.1038/s41581-019-0234-4
doi: 10.1038/s41440-024-01896-0 43. Al-Lamki RS, Mayadas TN. TNF receptors: Signaling
pathways and contribution to renal dysfunction. Kidney Int.
33. Breyer MD, Susztak K. The next generation of therapeutics
for chronic kidney disease. Nat Rev Drug Discov. 2015;87(2):281-296.
2016;15(8):568-588. doi: 10.1038/ki.2014.285
doi: 10.1038/nrd.2016.67 44. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty.
Immunity. 2012;36(4):503-514.
34. Provenzano M, Puchades MJ, Garofalo C, et al. Albuminuria-
lowering effect of dapagliflozin, eplerenone, and their doi: 10.1016/j.immuni.2012.03.013
combination in patients with chronic kidney disease: 45. Tuttle KR, Adler S, Kretzler M, et al. Baricitinib in diabetic
A randomized crossover clinical trial. J Am Soc Nephrol. kidney disease: Results from a phase 2, multicenter,
2022;33(8):1569-1580. randomized, double-blind, placebo-controlled study. In:
doi: 10.1681/ASN.2022020207 American Diabetes Association Meeting; 2015. p. 114.
35. Zhang Y, He D, Zhang W, et al. ACE inhibitor benefit to kidney 46. Ying Y, Kim J, Westphal SN, Long KE, Padanilam BJ. Targeted
and cardiovascular outcomes for patients with non-dialysis deletion of p53 in the proximal tubule prevents ischemic renal

Volume 2 Issue 1 (2025) 47 doi: 10.36922/imo.4969